- |||||||||| Proair digihaler (albuterol sulfate) / Teva, AirDuo Digihaler (salmeterol/fluticasone proprionate) / Teva
Enrollment closed, Heterogeneity: Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - May 9, 2023
P4, N=101, Active, not recruiting,
Recruiting --> Active, not recruiting
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Trial completion, Phase classification: Digihaler in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Apr 19, 2023
P=N/A, N=55, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Phase classification: P1 --> PN/A
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Objectively Recorded Peak Inspiratory Flow (PIF), Inhalation Volume and Reliever Medication Use Preceding COPD Exacerbations (Walter E. Washington Convention Center, Ballroom B (Level 3)) - Mar 25, 2023 - Abstract #ATS2023ATS_4082;
P=N/A
Use of an electronically enabled inhalation device capable of assessing inhalation frequency, flow and volume provides valuable data that may have utility in predicting an impending AECOPD and that could signal for early intervention. In addition, the sequence of changes among these variables may inform understanding of physiological processes underlying exacerbations, such as hyperinflation and respiratory muscle weakness, thereby potentially further enhancing their predictive value in the future.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
App-Based Symptom Assessment Is Triggered by Inhaler Use Changes Preceding COPD Exacerbations (Marriott Marquis Washington, Marquis Ballroom, Salons 1-2 (Level M2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2329;
P=N/A
Changes in inhalation parameters and inhaler use occur in the days preceding an AECOPD, and can provide objective triggers for automated symptom assessment. This has the potential to improve symptom assessments by enhancing patient awareness about objective changes in rescue use and inhalation parameters at the time they are happening.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Inhalation Technique Maintenance in COPD Patients Using the Albuterol Digihaler (Marriott Marquis Washington, Marquis Ballroom, Salons 1-2 (Level M2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2327;
P=N/A
The Digihaler System is able to record objective inhalation quality data, permitting assessment of patient efforts and technique. Data from the Digihaler System communicated to providers via the physician-facing dashboard may aid in assessing whether poor technique or other factors underlie clinical deterioration.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Enrollment closed: Digihaler in Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Dec 8, 2022
P1, N=55, Active, not recruiting,
Data from the Digihaler System communicated to providers via the physician-facing dashboard may aid in assessing whether poor technique or other factors underlie clinical deterioration. Recruiting --> Active, not recruiting
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Trial completion, Real-world evidence, Real-world: ProAir Digihaler in COPD Disease Management: A Real World Study (clinicaltrials.gov) - Jun 24, 2022
P=N/A, N=27, Completed,
This approach may support a shift from reactive care to proactive, preventative, and personalized management of chronic respiratory diseases. Active, not recruiting --> Completed
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Trial completion date, Trial primary completion date, Real-world evidence, Real-world: ProAir Digihaler in COPD Disease Management: A Real World Study (clinicaltrials.gov) - Apr 20, 2022
P=N/A, N=27, Active, not recruiting,
Active, not recruiting --> Completed Trial completion date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Enrollment closed, Enrollment change, Real-world evidence, Real-world: ProAir Digihaler in COPD Disease Management: A Real World Study (clinicaltrials.gov) - Dec 17, 2021
P=N/A, N=27, Active, not recruiting,
The advent of digital inhalers offers new potential to address this challenge and develop individualized preventive approaches informed by reliable reliever usage data. Recruiting --> Active, not recruiting | N=20 --> 27
- |||||||||| Proair digihaler (albuterol sulfate) / Teva, AirDuo Digihaler (salmeterol/fluticasone proprionate) / Teva
New P4 trial, Heterogeneity: Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - Aug 9, 2021
P4, N=100, Recruiting,
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Enrollment open, Real-world evidence, Real-world: ProAir Digihaler in COPD Disease Management: A Real World Study (clinicaltrials.gov) - May 12, 2021
P=N/A, N=20, Recruiting,
This early signalling may suggest disease deterioration, and potentially allow for pre-emptive, more effective personalised asthma management. Not yet recruiting --> Recruiting
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
[VIRTUAL] REMOTELY RECORDED PEAK INHALATION FLOW PATTERNS AMONG PATIENTS WITH COPD USING PROAIR DIGIHALER FOR RESCUE MEDICATION () - Oct 12, 2020 - Abstract #CHEST2020CHEST_2132;
Throughout the study, patients were able to generate a PIF above 30 L/min in 77.2 % of inhalation events, while the most common errors were opening and closing the cap without a detectable inhalation and multiple inhalations without closing the cap. CLINICAL IMPLICATIONS: Data collected by Digihaler could potentially support remote patient monitoring and shared decision-making by providing objective inhaler usage data for a dialogue between patient and healthcare provider.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
[VIRTUAL] A digital inhaler uncovering patterns of SABA use in asthma and COPD (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_2952;
P3
Integrated sensors in an electronic inhaler (ProAir Digihaler) record objective data on inhaler usage and, consequently, inhalation technique...Conclusions Visual displays of inhaler use data may help identify clinically meaningful information early and facilitate physician-patient interventions and conversations. Additional research is needed to assist clinical decisions and identify more complex data patterns to further interpretation.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
[VIRTUAL] Predictive Model for COPD Exacerbations Using ProAir Digihaler: A 12-Week, Open‑Label Study (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_387;
Digital electronic inhaler devices, such as the Digihaler, have the potential to allow clinicians to collect real-time data that may aid patient management. Additional studies are required to further develop, validate, and expand the predictive model, which may allow early intervention of clinical worsening of COPD and preempt more severe exacerbations, thereby avoiding emergency department visits and hospitalizations, and improving quality of life.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
A Predictive Model for COPD Exacerbations Using ProAir Digihaler: A 12-Week, Open‑Label Study (PENNSYLVANIA CONVENTION CENTER, Room 121 A-C (100 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_3595;
Digital electronic inhaler devices, such as the Digihaler, have the potential to allow clinicians to collect real-time data that may aid patient management. Additional studies are required to further develop, validate, and expand the predictive model, which may allow early intervention of clinical worsening of COPD and preempt more severe exacerbations, thereby avoiding emergency department visits and hospitalizations, and improving quality of life.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
Inhalation Parameters In Patients With Asthma Using Albuterol Electronic Multi-dose Dry Powder Inhaler (Convention Center, 200 Level, Hall D) - Mar 1, 2020 - Abstract #AAAAI2020AAAAI_1839;
ProAir Digihaler (albuterol 90 µg/dose) is an electronic multi‑dose dry powder inhaler designed with an integrated electronic module, which records objective information on inhaler usage and inhalation parameters, and thereby technique... Inhalation parameters recorded by Digihaler may indicate inhaler technique deterioration or changes in underlying lung physiology preceding a CAE, and could help identify patients at risk of CAEs who might benefit from further instruction or intervention, potentially supporting improved asthma management.
- |||||||||| Proair digihaler (albuterol sulfate) / Teva
An Updated Model For Prediction Of Asthma Exacerbations Using Albuterol Electronic Multi-dose Dry Powder Inhaler (Convention Center, 200 Level, Hall D) - Mar 1, 2020 - Abstract #AAAAI2020AAAAI_1836;
A predictive model for impending CAEs was successfully developed using data from ProAir Digihaler (albuterol 90 µg), an electronic multi-dose dry powder inhaler with integrated sensors...Combining Digihaler data with CRF information enabled the improvement of the predictive model. Additional studies, and potentially including other data sources, will further refine the model.
|
